Introduction
============

Coronary heart disease is one of the most common cardiovascular diseases in China, and acute myocardial infarction (AMI) is the type with the highest lethality and the worst prognosis ([@b1-etm-0-0-5930],[@b2-etm-0-0-5930]). A study has shown that hyperglycemia plays an important role in the formation of atherosclerosis (AS), and investigations have shown a high prevalence of diabetes mellitus type 2 (T2DM) in patients with coronary heart disease ([@b3-etm-0-0-5930]). A series of chronic inflammatory reactions occur in the body of patients with AMI combined with T2DM. This process causes massive accumulation of macrophages, dendritic cells, mast cells and T cells, which promote arterial inflammation by releasing inflammatory cytokines, thus leading to the formation of coronary plaques ([@b4-etm-0-0-5930],[@b5-etm-0-0-5930]). Therefore, inflammatory cytokines in serum can be used to predict the formation of coronary plaques as well as their development and changes, and further used to monitor changes in coronary heart disease condition in patients and determine their prognoses ([@b6-etm-0-0-5930]--[@b8-etm-0-0-5930]). Hypersensitive plasma pentraxin-3 (PTX3) is a marker of inflammatory reaction and can be expressed in atherosclerotic plaques. PTX3 is closely related to endothelial cells, and the concentration of PTX3 in serum can reflect the inflammatory state of arteries *in vivo* ([@b9-etm-0-0-5930]). The abnormal lipid metabolism of T2DM is the most important cause of vascular complications in patients with DM. The change in the ratio of plasma apolipoprotein A1 (ApoA1) to apolipoprotein B (ApoB) can reflect the dynamic balance between anti-AS factors and pro-AS factors, and APoA1/ApoB can be regarded as a relatively good predictor for the onset risks of cardiovascular and cerebrovascular diseases ([@b10-etm-0-0-5930]). A study has shown that hemoglobin A1c (HbAlc) is a relatively good clinical indicator reflecting blood glucose control status, and it can also indirectly reflect the severity of DM in patients; elevated serum level of HbA1c will lead to increased risk of cardiovascular diseases such as MI ([@b11-etm-0-0-5930]).

In the present study, differences in serum levels of PTX3, HbAlc and ApoA1/ApoB in patients with MI combined with T2DM, patients only with MI and healthy people were detected, so as to compare the differences in the concentration of the three indexes in different numbers of diseased coronary artery vessels and different groups, analyzing the effects of PTX3, HbAlc and ApoA1/ApoB judging the severity of MI combined with T2DM in patients and evaluating the prognosis.

Materials and methods
=====================

### Study objects

A case-control study was conducted, in which 100 patients with AMI combined with T2DM hospitalized in the Department of Cardiology of People\'s Hospital of Dongying (Dongying, China) from January 2013 to August 2017 were selected as Group A. According to the level of fasting blood glucose (FBG), these patients were subdivided into Group A1 with FBG ≥13.0 mmol/l and Group A2 with FBG \<13.0 mmol/l. A total of 100 hospitalized patients with AMI in People\'s Hospital of Dongying were collected as Group B, and 100 healthy people receiving physical examination in the Physical Examination Center of People\'s Hospital of Dongying were selected as Group C. The study was approved by the Ethics Committee of People\'s Hospital of Dongying (Dongying, China) and written informed consents were signed by the patients and/or guardians.

### Diagnostic methods

Diagnostic criteria for AMI were according to the Diagnostic Criteria for Coronary Atherosclerotic Heart Disease in the 2010 Hygiene Standards of the People\'s Republic of China ([@b12-etm-0-0-5930]): i) patients with a clinical history of ischemic chest pain; ii) patients whose electrocardiogram showed dynamic evolution; and iii) patients with dynamic changes in the concentration of serum myocardial markers of myocardial necrosis. Patients meeting 2 or 3 criteria above can be diagnosed as AMI.

Diagnostic criteria for patients with DM were based on the criteria formulated by the World Health Organization in 1999 ([@b13-etm-0-0-5930]): patients showing DM symptoms with intravenous plasma FBG ≥7.0 mmol/l at any time, random blood glucose ≥11.1 mmol/l, or 2 h blood glucose ≥11.1 mmol/l shown in an oral glucose tolerance test (OGTT).

Patients with malignant tumors, acute and chronic infectious diseases, severe liver and kidney dysfunction, immune system diseases, DM type I or ketoacidosis, pregnant women and minors under 18 years old were excluded.

### Data collection methods

Basic data of the participants were collected, including age, weight, height, sex, smoking history and blood pressure value. Fasting venous blood was collected after 12-h fasting, and the levels of PTX3, HbAlc and ApoA1/ApoB were measured.

The results of coronary angiography were collected. Divisions of the number of vascular lesions in patients in the AMI combined with T2DM group and the AMI group: A lesion involving any one of the anterior descending branch, circumflex branch, or right coronary artery was identified as a single-vessel lesion; a lesion involving any two of them was determined as a double-vessel lesion; a lesion involving all the three branches was judged as a triple-vessel lesion; the left main coronary artery lesion was identified as a triple-vessel lesion.

### Detection methods

The concentration of PTX3 was determined by enzyme-linked immunosorbent assay (Gbd Group, Inc., Woodbridge, VA, USA), and those of ApoA1 and ApoB were determined by an automatic biochemical analyzer. The percentage of HbA1c was determined by ion exchange high-performance liquid chromatography (HPLC) automatic analyzer.

### Statistical analysis

SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Chi-square test was used for qualitative data, and partitioning of Chi-square was used for pairwise comparisons. The normally distributed quantitative data were analyzed by analysis of variance or t-test; pairwise comparisons were detected by Student-Newman-Keuls-Q (SNK-Q) test; the non-normally distributed quantitative data were detected by rank-sum test. The relationship of the number of diseased coronary artery vessels with each index was analyzed by Spearman\'s correlation analysis and logistic regression analysis. All P-values represented bilateral probability and significance level was set as 0.05.

Results
=======

In this study, a total of 100 patients with AMI combined with T2DM were enrolled. Among them, there were 44 patients with FBG ≥13.0 mmol/l (Group A1) and 56 patients with FBG \<13.0 mmol/l (Group A2); there were 100 patients with AMI (Group B), and 100 healthy people in the Physical Examination Center (Group C).

### Comparisons of basic data among each group

There were no statistical significant differences in sex, age and body mass index among Group A1, A2, B and C (P\>0.05). The proportions of patients who smoked in Group A1, A2 and B were higher than that in Group C (P\<0.05); the systolic and diastolic blood pressure in Group A1 and A2 were significantly higher than those in Group B and C (P\<0.05); the level of FBG in Group A1 was higher than that in Group A2 (P\<0.05); the level of FBG in Group A2 was higher than those in Group B and C (P\<0.05); there was no statistical significant difference in FBG between Group B and C (P\<0.05) ([Table I](#tI-etm-0-0-5930){ref-type="table"}).

### Comparisons of PTX3, HbAlc and ApoA1/ApoB among the four groups of patients

PTX3 level was the highest in Group A1, followed by Group A2, Group B and Group C (P\<0.05). HbAlc and ApoA1/ApoB were the lowest in Group A1, followed by Group A2 (P\<0.05), but there was no significant difference between Group B and C (P\>0.05); HbAlc in Group A1 was significantly higher than that in Group A2 (P\<0.01) ([Table II](#tII-etm-0-0-5930){ref-type="table"}).

### Comparison of the numbers of diseased coronary artery vessels between the AMI combined with T2DM group and the AMI group

Comparisons of the numbers of diseased coronary artery vessels among Group A1, A2 and B showed that the number of diseased coronary artery vessels in Group A1 was significantly larger than those in Group A2 and B (P\<0.05); the number of diseased coronary artery vessels in Group A2 was the largest (P\<0.05), followed by Group A1, and finally Group B; the numbers of single-vessel coronary artery lesions in Group A1 and A2 were smaller than that in Group B (P\<0.05) ([Table III](#tIII-etm-0-0-5930){ref-type="table"}).

### Correlation of the number of diseased coronary artery vessels with PTX, HbAlc and ApoA1/ApoB

Spearman\'s rank correlation analysis showed that the number of diseased coronary artery vessels was positively correlated with PTX3 and HbA1c (r=0.667, P=0.001; r=0.548, P\<0.008), but negatively correlated with ApoA1/ApoB (r=−0.710, P\<0.001). Logistic regression analysis revealed that PTX3 and HbA1c were risk factors for the number of diseased coronary artery vessels \[odds ratio (OR)=2.575, 95% confidence interval (95% CI): 1.717--3.433; OR=1.986, 95% CI, 1.357--2.597\], and ApoA1/ApoB was a protective factor for the number of diseased coronary artery vessels (OR=0.186, 95% CI, 0.153--0.237) ([Tables IV](#tIV-etm-0-0-5930){ref-type="table"} and [V](#tV-etm-0-0-5930){ref-type="table"}).

Discussion
==========

The occurrence and development of coronary heart disease are closely related to atherosclerosis (AS), and AS is formed by a variety of inflammatory cytokines in the body involved in various factors. DM is an independent risk factor for patients with coronary heart disease. In patients with coronary heart disease combined with T2DM, the persistent chronic hyperglycemia in the body damages the blood vessel wall and endothelial cells, and the action of a variety of inflammatory cytokines leads to the formation of atherosclerotic plaques, thus resulting in or accelerating the occurrence and development of coronary heart disease and other atherosclerotic lesions ([@b13-etm-0-0-5930],[@b14-etm-0-0-5930]). A number of studies in China and elsewhere indicated that there are correlations of serum PTX3, HbAlc and ApoA1/ApoB with the change in the condition of coronary heart disease or DM in patients and their prognoses ([@b10-etm-0-0-5930]--[@b12-etm-0-0-5930]). Therefore, in this study, serum levels of PTX3, HbAlc and ApoA1/ApoB in patients with AMI combined with T2DM were measured, and the effects of PTX3, HbAlc and ApoA1/ApoB in the diagnosis and prognosis evaluation of these patients were analyzed.

Pentraxin-3 (PTX3) is an inflammatory cytokine that is secreted by vascular endothelial cells and macrophages under the action of various inflammatory cytokines. PTX3 can be expressed in atherosclerotic plaques, and the increased concentration of it can reflect the activation and instability of atherosclerotic plaques; PTX-3 has been proved to be involved in the occurrence and development of many cardiovascular diseases ([@b10-etm-0-0-5930],[@b15-etm-0-0-5930],[@b16-etm-0-0-5930]). The study revealed that the level of PTX3 in patients with AMI combined with T2DM in Group A1 was the highest, followed by patients with AMI combined with T2DM and AMI patients in Group A2, and the lowest level appeared in healthy people, indicating that patients with AMI combined with T2DM have the highest degree of inflammatory responses, severe vascular endothelial injuries and unstable atherosclerotic plaques.

HbA1c is a product of non-enzymatic glycation reaction of hemoglobin which occurs slowly and continuously under the action of hyperglycemia. The increase of HbA1c leads to the acceleration of vasoconstriction, which increases gene expression of chemokines and adhesion molecules, speeds up lymphocytes and monocytes transferring into the vessel wall, and promotes the formation of atherosclerotic plaques ([@b17-etm-0-0-5930]--[@b19-etm-0-0-5930]). HbA1c is a commonly used clinical indicator for glycemic control in DM, and it can indirectly reflect the severity of DM condition in patients. The increased HbA1c may increase the onset risk of cardiovascular disease ([@b20-etm-0-0-5930],[@b21-etm-0-0-5930]). It was found in this study that HbA1c level in Group A1 was significantly higher than that in Group A2, that in Group A2 was higher than that in Group B, and that in Group B had no difference with Group C, indicating that the higher the level of HbA1c in patients with coronary heart disease combined with MI, the more severe the DM condition will be.

ApoAl is the major apolipoprotein of high-density lipoprotein (HDL), which acts to transport cholesterol from the tissues of the body to the liver for catabolism, thereby preventing the deposition of cholesterol in the blood vessel wall. Therefore, ApoAl has the role of inhibiting the atherosclerotic plaque formation. ApoB is the major apolipoprotein of low-density lipoprotein cholesterol (LDL-C), and LDL-C, an integral part of atherosclerotic plaques, is a major risk factor for AS. Therefore, the increased ApoB is an indicator for predicting the high onset risk of coronary heart disease ([@b22-etm-0-0-5930]). The ratio of plasma ApoA1 to ApoB can indirectly reflect the balance between anti-AS factors and pro-AS factors in plasma ([@b23-etm-0-0-5930]--[@b25-etm-0-0-5930]). This study showed that ApoA1/ApoB in Group A1 was lower than that in Group A2, but there was no difference between Group B and C, indicating that the degree of AS in DM patients is relatively high, and the occurrence risk of cardiovascular events is also high.

In addition, Spearman\'s rank correlation analysis manifested that the number of diseased coronary artery vessels was positively associated with PTX3 and HbA1c, but negatively associated with ApoA1/ApoB. Multivariate linear regression analysis showed that PTX3 and HbA1c were risk factors for the number of diseased coronary artery vessels, but ApoA1/ApoB was a protective factor for it, suggesting that with the increase in PTX3 and HbA1c and the decrease in ApoA1/ApoB in serum of AMI patients, the degree of coronary artery lesion will become more severe.

In summary, increased inflammatory responses (elevated PTX3), aggravated DM (elevated HbA1c) and lipid metabolism disorders (decreased ApoA1/ApoB) may occur in patients with AMI combined with T2DM. Therefore, PTX3, HbAlc and ApoA1/ApoB can be used to determine the severity of AMI combined with T2DM, assess the prognosis of patients and provide a basis for improving treatment programs.
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###### 

Comparisons of basic data among each group (mean ± SD).

  Factors                     A1 group (n=44)                                                                                           A2 group (n=56)                                                                                           B group (n=100)                                       C group (n=100)
  --------------------------- --------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -----------------
  Sex (male/female)           22/20                                                                                                     29/26                                                                                                     56/44                                                 51/49
  Age (years)                 61.88±9.18                                                                                                62.09±10.25                                                                                               60.30±9.33                                            59.89±11.50
  Body mass index (kg/m^2^)   24.91±3.21                                                                                                23.32±4.58                                                                                                23.97±3.87                                            23.10±2.12
  Smoking history (%)         50.00^[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^                                                       46.43^[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^                                                       52.00^[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^   18.00
  SBP (mmHg)                  148.08±15.28^[b](#tfn2-etm-0-0-5930){ref-type="table-fn"},[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^   147.70±14.27^[b](#tfn2-etm-0-0-5930){ref-type="table-fn"},[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^   126.50±13.68                                          123.35±12.80
  DBP (mmHg)                  88.84±3.51^[b](#tfn2-etm-0-0-5930){ref-type="table-fn"},[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^     86.04±4.25^[b](#tfn2-etm-0-0-5930){ref-type="table-fn"},[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^     77.56±2.60                                            76.69±1.46
  FBG (mmmol/l)               16.32±2.26^[a](#tfn1-etm-0-0-5930){ref-type="table-fn"}--[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^    8.66±3.57^[b](#tfn2-etm-0-0-5930){ref-type="table-fn"},[c](#tfn3-etm-0-0-5930){ref-type="table-fn"}^      5.50±0.98                                             5.28±0.81

Compared with Group A2, P\<0.05

compared with Group B, P\<0.05

compared with Group C, P\<0.05.

###### 

Comparisons of PTX3, HbAlc and ApoA1/ApoB among the four groups of patients (mean ± SD).

  Testing indexes   A1 group (n=44)                                                                                             A2 group (n=56)                                                                                          B group (n=100)                                           C group (n=100)
  ----------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -----------------
  PTX3 (µg/l)         7.54±0.43^[a](#tfn4-etm-0-0-5930){ref-type="table-fn"}--[c](#tfn6-etm-0-0-5930){ref-type="table-fn"}^     6.68±0.57^[b](#tfn5-etm-0-0-5930){ref-type="table-fn"},[c](#tfn6-etm-0-0-5930){ref-type="table-fn"}^     5.62±0.53^[c](#tfn6-etm-0-0-5930){ref-type="table-fn"}^   1.67±0.81
  HbA1c (%)         10.82±0.61^[d](#tfn7-etm-0-0-5930){ref-type="table-fn"}--[f](#tfn9-etm-0-0-5930){ref-type="table-fn"}^      8.50±0.57^[d](#tfn7-etm-0-0-5930){ref-type="table-fn"},[e](#tfn8-etm-0-0-5930){ref-type="table-fn"}^     7.26±0.68                                                 6.59±0.62
  ApoA1/ApoB          1.12±0.23^[g](#tfn10-etm-0-0-5930){ref-type="table-fn"}--[i](#tfn12-etm-0-0-5930){ref-type="table-fn"}^   1.28±0.19^[g](#tfn10-etm-0-0-5930){ref-type="table-fn"},[h](#tfn11-etm-0-0-5930){ref-type="table-fn"}^   1.49±0.30                                                 1.76±0.43

Compared with Group A2, P\<0.05

compared with Group B, P\<0.05

compared with Group C, P\<0.05

compared with Group A2, P\<0.01

compared with Group B, P\<0.05

compared with Group C, P\<0.05

compared with Group A2, P\<0.01

compared with Group B, P\<0.05

compared with Group C, P\<0.05.

###### 

Comparison of the number of diseased coronary artery vessels between the AMI combined with T2DM group and the AMI group \[n (%)\].

                    Nos. of diseased coronary artery vessels                                                                                                                                                                          
  ---------- ------ ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  A1 group     44   3 (6.82)^[a](#tfn13-etm-0-0-5930){ref-type="table-fn"},[b](#tfn14-etm-0-0-5930){ref-type="table-fn"}^   17 (38.64)^[c](#tfn15-etm-0-0-5930){ref-type="table-fn"},[d](#tfn16-etm-0-0-5930){ref-type="table-fn"}^   24 (54.54)^[e](#tfn17-etm-0-0-5930){ref-type="table-fn"},[f](#tfn18-etm-0-0-5930){ref-type="table-fn"}^
  A2 group     56   8 (14.29)^[b](#tfn14-etm-0-0-5930){ref-type="table-fn"}^                                                34 (60.71)^[d](#tfn16-etm-0-0-5930){ref-type="table-fn"}^                                                 14 (25.00)
  B group    100    55 (55.00)                                                                                              25 (25.00)                                                                                                20 (20.00)

Compared with Group A2, P\<0.05

compared with Group B, P\<0.05

compared with Group A2, P\<0.05

compared with Group B, P\<0.05

compared with Group A2, P\<0.05

compared with Group B, P\<0.05.

###### 

Correlation analyses of the number of diseased coronary artery vessels with serum PTX3, HbA1c and ApoA1/ApoB.

               Nos. of diseased coronary artery vessels   
  ------------ ------------------------------------------ ---------
  PTX3         0.667                                      0.001
  HbA1c        0.548                                      0.008
  ApoA1/ApoB   −0.710                                     \<0.001

###### 

Logistic regression analyses of the number of diseased coronary artery vessels with serum PTX3, HbA1c and ApoA1/ApoB.

  Factors      B        SE      Wald    P-value   OR      95% CI
  ------------ -------- ------- ------- --------- ------- --------------
  PTX3         0.946    0.438   5.893   0.012     2.575   1.717--3.433
  HbA1c        0.686    0.321   4.813   0.041     1.986   1.357--2.597
  ApoA1/ApoB   −1.618   0.589   8.947   \<0.001   0.186   0.153--0.237
